Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2025,
Susmed paid円0.0 Mil more to buy back shares than it received from issuing new shares.
It received円0.0 Mil from issuing more debt.
It paid円0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received円0.0 Mil from paying cash dividends to shareholders.
It received円0.0 Mil on other financial activities.
In all, Susmedspent円0.0 Mil on financial activities for the
three
months ended in Dec. 2025.
Susmed (TSE:4263) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Susmed's issuance of stock for the
three
months ended in Dec. 2025 was 円0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Susmed's repurchase of stock for the
three
months ended in Dec. 2025 was 円0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Susmed's net issuance of debt for the
three
months ended in Dec. 2025 was 円0.0 Mil.
Susmed received円0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Susmed's net issuance of preferred for the
three
months ended in Dec. 2025 was 円0.0 Mil.
Susmed paid円0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Susmed's cash flow for dividends for the
three
months ended in Dec. 2025 was 円0.0 Mil.
Susmed received円0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Susmed's other financing for the
three
months ended in Dec. 2025 was 円0.0 Mil.
Susmed received円0.0 Mil on other financial activities.
Susmed Cash Flow from Financing Related Terms
Susmed Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Susmed's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Susmed's Cash from Financing for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of 円0.0 Mil mean?
Susmed (TSE:4263) has a Cash Flow from Financing of 円0.0 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Susmed and its competitors.
Is Susmed's Cash Flow from Financing too high?
Susmed's current Cash Flow from Financing is 円0.0 Mil. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Cash Flow from Financing compare to VEEV and BTSG?
Susmed's Cash Flow from Financing of 円0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Susmed and its competitors. Susmed's current Cash Flow from Financing is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円939.36, compared to a current price of 円708.00 — trading 24.6% below its estimated fair value. The current Cash Flow from Financing is 円0.0 Mil. Susmed's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Susmed (TSE:4263), the current Cash Flow from Financing is 円0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円708.00 is trading 24.6% below its estimated GF Value™ of 円939.36.
GuruFocus considers Susmed to be Modestly Undervalued.
Key valuation signals for TSE:4263:
Cash Flow from Financing: 円0.0 Mil
GF Value™: 円939.36 vs. price of 円708.00 (24.6% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score
Get the complete analysis for TSE:4263
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
